Clinical trials: Ovarian Tumor
Polycystic Ovary Syndrome
The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder of reproductive-age women. According to Rotterdam 2003 criteria: at least two of three criteria are met, hyperandrogenism, chronic anovulation, and…
- Trial name
- NCT01117272
- Where
- Taiwan
- Volunteers
- 474 people
- Sponsor
- Taipei Medical University WanFang Hospital
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Ovarian Cancer
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
This is a prospective non-randomized efficacy trial of olaparib maintenance therapy after frontline treatment with platinum-based therapy in advanced ovarian cancer patients with BRCAwt, homologous recombination deficient (HRD)…
- Trial name
- NCT06120972
- Testing
- Olaparib tablet
- Sponsor
- Alexander B Olawaiye, MD
Relapsed Ovarian Cancer
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with…
- Trial name
- NCT05607329
- Testing
- Secondary cytoreduction, Chemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Ovarian Cancer
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
- Trial name
- NCT04724031
- Testing
- PARP inhibitor
- Where
- Greece
- Volunteers
- 180 people
- Sponsor
- Hellenic Cooperative Oncology Group
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Epithelial Ovarian Cancer, Peritoneal Cancer
HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
The combination of optimal cytoreductive operation (according to Desktop II criteria), HIPEC with Carboplatin 800 mg/m² KOF (Körperoberfläche) and following platinum-based systemic chemotherapy should be executed In patients with…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- HIPEC (NCT02487849)
- Testing
- HIPEC, Carboplatin
- Where
- Austria
- Sponsor
- Krankenhaus Barmherzige Schwestern Linz
Ovarian Cancer, Fallopian Tube Cancer
Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
The purpose of this study is to explore the experiences of Black women who receive care for ovarian cancer at Memorial Sloan Kettering Cancer Center, or "MSK" for short.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02928549
- Testing
- semi-structured interviews
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
This is a single arm phase II study with a combination of Hycamptin® (topotecan) and erlotinib for a minimum of 2 cycles in patients (18 yrs of age and older) with recurrent ovarian cancer previously treated with chemotherapy…
- Trial name
- NCT01003938
- Testing
- Topotecan, Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Polycystic Ovary Syndrome
AMH, Glucose Intolerance and Metabolic Syndrome in PCOS
Association between serum anti-Mullerian hormone (AMH) level and prevalence of glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS)
- Trial name
- NCT02676518
- Testing
- serum
- Where
- Thailand
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Breast Cancer, Ovarian Cancer
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Chimeric antigen receptor T cells (CAR-T) therapy has not yet been fully explored in solid tumors. Human epidermal growth factor receptor-2(HER2) is widely expressed in cancers.
- Conditions
- Breast Cancer, Ovarian Cancer, Lung Cancer, Gastric Cancer
- Trial name
- NCT02713984
- Testing
- Anti-HER2 CAR-T
- Where
- China
- Sponsor
- Zhi Yang
Treatment Related Cancer, Ovarian Cancer
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.
- Trial name
- NCT06562647
- Testing
- SY001
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Cell Origin Biotech (Hangzhou) Co., Ltd.
Ovarian Cancer
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT01684878
- Testing
- Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer
The goal of this observational study is to develop an exosome-based scoring model for post-treatment surveillance of recurrence in ovarian cancer. The main questions it aims to answer are: 1.
- Trial name
- NCT06925126
- Testing
- Not applicable- observational study
- Volunteers
- 200 people
- Sponsor
- Fudan University
High Grade Ovarian Cancer, Primary Peritoneal Cancer
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade…
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05456685
- Testing
- Mirvetuximab soravtansine, Carboplatin
- Where
- 69 sites in United States, Belgium and 4 more
- Volunteers
- 125 people
- Sponsor
- AbbVie
Advanced Solid Tumor, Ovarian Cancer
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary
- Trial name
- NCT05252390
- Testing
- NUV-868, Olaparib, Enzalutamide
- Where
- 22 sites in United States, Australia
- Volunteers
- 82 people
- Sponsor
- Nuvation Bio Inc.
BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study
The aim of the study is to explore a prognostic clinical and molecular biomarker profile in a population of BRCA wild-type recurrent high-grade ovarian cancer patients treated with olaparib as maintenance after response to a…
- Trial name
- MITO 31 (NCT04091204)
- Testing
- Olaparib tablets
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Cancer of Ovary, Cancer of the Ovary
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
This study will evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a…
- Conditions
- Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer
- Trial name
- NCT02432378
- Testing
- Cisplatin + celecoxib + DC vaccine, Cisplatin + CKM + Celecoxib + DC Vaccine
- Where
- 2 sites in United States
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.